Skip to main content
Erschienen in: Surgical Endoscopy 11/2020

09.12.2019

Effects of laparoscopic splenectomy and azygoportal disconnection on liver synthesis function and cirrhosis: a 2-year prospective study

verfasst von: Dou-Sheng Bai, Bao-Huan Zhou, Jian-Jun Qian, Chi Zhang, Sheng-Jie Jin, Guo-Qing Jiang

Erschienen in: Surgical Endoscopy | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Laparoscopic splenectomy and azygoportal disconnection (LSD) is widely used for the treatment of esophagogastric variceal haemorrhage and hypersplenism owing to cirrhotic portal hypertension. However, whether LSD improves liver synthesis function and cirrhosis remains unclear. The aim of this study is to investigate the effect of LSD on liver synthesis function and cirrhosis based on a prospective 2-year follow-up study.

Methods

A total of 118 patients with cirrhotic portal hypertension who underwent LSD were included in this study. We analysed clinical data including routine blood parameters, liver function, liver-synthesised proteins (antithrombin III, protein S, and protein C), liver fibrotic markers (type IV collagen (IV-C), procollagen type III (PC-III), laminin, and hyaluronidase), portal vein diameter, and portal blood flow velocity.

Results

Postoperative portal vein diameter and portal blood flow velocity all showed gradual declines during the 2-year follow-up; compared with preoperative values, these were all significantly decreased from postoperative week (POW) 1 (all P < 0.001). Postoperative Child–Pugh scores and total bilirubin, albumin, international normalised ratio, antithrombin III, protein S, protein C, IV-C, PC-III, laminin, and hyaluronidase levels also all showed gradual improvements during the 2-year follow-up; compared with preoperative levels, these were all significantly improved from postoperative month (POM) 6, POW 1, POM 3, POM 3, POM 3, POM 6, POM 18, POW 1, POM 3, POM 24, and POM 18, respectively (all P < 0.05).

Conclusion

LSD not only decreases portal hypertension and improves liver function, it also enhances liver synthesis function and reduces liver fibrosis.
Literatur
1.
Zurück zum Zitat Strader DB, Wright T, Thomas DL, Seeff LB, Diagnosis, management, and treatment of hepatitis C (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171PubMedCrossRef Strader DB, Wright T, Thomas DL, Seeff LB, Diagnosis, management, and treatment of hepatitis C (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171PubMedCrossRef
2.
Zurück zum Zitat Schiedermaier P (2004) Splanchnic hemodynamics: cirrhotic versus non-cirrhotic portal hypertension. J Gastroenterol Hepatol 19:S150–S154CrossRef Schiedermaier P (2004) Splanchnic hemodynamics: cirrhotic versus non-cirrhotic portal hypertension. J Gastroenterol Hepatol 19:S150–S154CrossRef
3.
Zurück zum Zitat Hong WD, Zhu QH, Huang ZM, Chen XR, Jiang ZC, Xu SH, Jin K (2009) Predictors of esophageal varices in patients with HBV-related cirrhosis: a retrospective study. BMC Gastroenterol 9:11PubMedPubMedCentralCrossRef Hong WD, Zhu QH, Huang ZM, Chen XR, Jiang ZC, Xu SH, Jin K (2009) Predictors of esophageal varices in patients with HBV-related cirrhosis: a retrospective study. BMC Gastroenterol 9:11PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Jensen DM (2002) Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology 122:162–1630CrossRef Jensen DM (2002) Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology 122:162–1630CrossRef
5.
Zurück zum Zitat LaBerge JM, Somberg KA, Lake JR, Gordon RL, Kerlan RK Jr, Ascher NL, Roberts JP, Simor MM, Doherty CA, Hahn J et al (1995) Two-year out-come following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 108:1143–1151PubMedCrossRef LaBerge JM, Somberg KA, Lake JR, Gordon RL, Kerlan RK Jr, Ascher NL, Roberts JP, Simor MM, Doherty CA, Hahn J et al (1995) Two-year out-come following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 108:1143–1151PubMedCrossRef
6.
Zurück zum Zitat Casado M, Bosch J, García-Pagán JC, Bru C, Bañares R, Bandi JC, Escorsell A, Rodríguez-Láiz JM, Gilabert R, Feu F, Schorlemer C, Echenagusia A, Rodés J (1998) Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 114:1296–1303PubMedCrossRef Casado M, Bosch J, García-Pagán JC, Bru C, Bañares R, Bandi JC, Escorsell A, Rodríguez-Láiz JM, Gilabert R, Feu F, Schorlemer C, Echenagusia A, Rodés J (1998) Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 114:1296–1303PubMedCrossRef
7.
Zurück zum Zitat Sanyal AJ, Freedman AM, Luketic VA, Purdum PP 3rd, Shiffman ML, DeMeo J, Cole PE, Tisnado J (1997) The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 112:889–898PubMedCrossRef Sanyal AJ, Freedman AM, Luketic VA, Purdum PP 3rd, Shiffman ML, DeMeo J, Cole PE, Tisnado J (1997) The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 112:889–898PubMedCrossRef
8.
Zurück zum Zitat Sugawara Y, Yamamoto J, Shimada K, Yamasaki S, Kosuge T, Takayama T, Makuuchi M (2000) Splenectomy in patients with hepatocellular carcinoma and hypersplenism. J Am Coll Surg 190:446–450PubMedCrossRef Sugawara Y, Yamamoto J, Shimada K, Yamasaki S, Kosuge T, Takayama T, Makuuchi M (2000) Splenectomy in patients with hepatocellular carcinoma and hypersplenism. J Am Coll Surg 190:446–450PubMedCrossRef
9.
Zurück zum Zitat Cao ZX, Chen XP, Wu ZD (2003) Changes of immune function in patients with liver cirrhosis after splenectomy combined with resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2:562–565PubMed Cao ZX, Chen XP, Wu ZD (2003) Changes of immune function in patients with liver cirrhosis after splenectomy combined with resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2:562–565PubMed
10.
Zurück zum Zitat Okuno K, Tanaka A, Shigeoka H, Hirai N, Kawai I, Kitano Y, Yasutomi M (1999) Suppression of T-cell function in gastric cancer patients after total gastrectomy with splenectomy: implications of splenic autotransplantation. Gastric Cancer 2:20–25PubMedCrossRef Okuno K, Tanaka A, Shigeoka H, Hirai N, Kawai I, Kitano Y, Yasutomi M (1999) Suppression of T-cell function in gastric cancer patients after total gastrectomy with splenectomy: implications of splenic autotransplantation. Gastric Cancer 2:20–25PubMedCrossRef
12.
Zurück zum Zitat Chen XP, Wu ZD, Huang ZY, Qiu FZ (2005) Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg 92:334–339PubMedCrossRef Chen XP, Wu ZD, Huang ZY, Qiu FZ (2005) Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg 92:334–339PubMedCrossRef
13.
Zurück zum Zitat Shimada M, Hashizume M, Shirabe K, Takenaka K, Sugimachi K (2000) A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism. Performing a hepatectomy after a laparoscopic splenectomy. Surg Endosc 14:127–130PubMedCrossRef Shimada M, Hashizume M, Shirabe K, Takenaka K, Sugimachi K (2000) A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism. Performing a hepatectomy after a laparoscopic splenectomy. Surg Endosc 14:127–130PubMedCrossRef
14.
Zurück zum Zitat Watanabe M, Murata S, Hashimoto I, Nakano Y, Ikeda O, Aoyagi Y, Matsuo R, Fukunaga K, Yasue H, Ohkohchi N (2009) Platelets contribute to the reduction of liver fibrosis in mice. J Gastroenterol Hepatol 24:78–89PubMedCrossRef Watanabe M, Murata S, Hashimoto I, Nakano Y, Ikeda O, Aoyagi Y, Matsuo R, Fukunaga K, Yasue H, Ohkohchi N (2009) Platelets contribute to the reduction of liver fibrosis in mice. J Gastroenterol Hepatol 24:78–89PubMedCrossRef
15.
Zurück zum Zitat Yu H, Guo S, Wang L, Dong Y, Tian G, Mu S, Zhang H, Li D, Zhao S (2016) Laparoscopic splenectomy and esophagogastric devascularization for liver cirrhosis and portal hypertension is a safe, effective, and minimally invasive operation. Laparoendosc Adv Surg Technol A 26:524–530CrossRef Yu H, Guo S, Wang L, Dong Y, Tian G, Mu S, Zhang H, Li D, Zhao S (2016) Laparoscopic splenectomy and esophagogastric devascularization for liver cirrhosis and portal hypertension is a safe, effective, and minimally invasive operation. Laparoendosc Adv Surg Technol A 26:524–530CrossRef
16.
Zurück zum Zitat Bai DS, Qian JJ, Chen P, Yao J, Wang XD, Jin SJ, Jiang GQ (2014) Modified laparoscopic and open splenectomy and azygoportal disconnection for portal hypertension. Surg Endosc 28:257–264PubMedCrossRef Bai DS, Qian JJ, Chen P, Yao J, Wang XD, Jin SJ, Jiang GQ (2014) Modified laparoscopic and open splenectomy and azygoportal disconnection for portal hypertension. Surg Endosc 28:257–264PubMedCrossRef
17.
Zurück zum Zitat Zhe C, Jian-wei L, Jian C, Yu-dong F, Ping B, Shu-guang W, Shu-guo Z (2013) Laparoscopic versus open splenectomy and esophagogastric devascularization for bleeding varices or severe hypersplenism: a comparative study. J Gastrointest Surg 17:654–659PubMedCrossRef Zhe C, Jian-wei L, Jian C, Yu-dong F, Ping B, Shu-guang W, Shu-guo Z (2013) Laparoscopic versus open splenectomy and esophagogastric devascularization for bleeding varices or severe hypersplenism: a comparative study. J Gastrointest Surg 17:654–659PubMedCrossRef
18.
Zurück zum Zitat Jiang GQ, Bai DS, Chen P, Qian JJ, Jin SJ, Yao J, Wang XD (2014) Modified laparoscopic splenectomy and azygoportal disconnection combined with cell salvage is feasible and might reduce the need for blood transfusion. World J Gastroenterol 20:18420–18426PubMedPubMedCentralCrossRef Jiang GQ, Bai DS, Chen P, Qian JJ, Jin SJ, Yao J, Wang XD (2014) Modified laparoscopic splenectomy and azygoportal disconnection combined with cell salvage is feasible and might reduce the need for blood transfusion. World J Gastroenterol 20:18420–18426PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat International Committee of Medical Journal Editors (2010) Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. J Pharmacol Pharmacother 1:42–58CrossRef International Committee of Medical Journal Editors (2010) Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. J Pharmacol Pharmacother 1:42–58CrossRef
20.
Zurück zum Zitat Bai DS, Xia BL, Zhang C, Ye J, Qian JJ, Jin SJ, Jiang GQ (2019) Warfarin versus aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection: a randomized clinical trial. Int J Surg 64:16–23PubMedCrossRef Bai DS, Xia BL, Zhang C, Ye J, Qian JJ, Jin SJ, Jiang GQ (2019) Warfarin versus aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection: a randomized clinical trial. Int J Surg 64:16–23PubMedCrossRef
21.
Zurück zum Zitat Akahoshi T, Tomikawa M, Kawanaka H, Furusyo N, Kinjo N, Tsutsumi N, Nagao Y, Hayashi J, Hashizume M, Maehara Y (2012) Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia. J Gastroenterol Hepatol 27:286–290PubMedCrossRef Akahoshi T, Tomikawa M, Kawanaka H, Furusyo N, Kinjo N, Tsutsumi N, Nagao Y, Hayashi J, Hashizume M, Maehara Y (2012) Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia. J Gastroenterol Hepatol 27:286–290PubMedCrossRef
22.
Zurück zum Zitat Akahoshi T, Tomikawa M, Korenaga D, Ikejiri K, Saku M, Takenaka K (2010) Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surg Endosc 24:680–685PubMedCrossRef Akahoshi T, Tomikawa M, Korenaga D, Ikejiri K, Saku M, Takenaka K (2010) Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surg Endosc 24:680–685PubMedCrossRef
23.
Zurück zum Zitat Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL, Italian Association of the Study of the Liver Disease (AISF) (2007) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45:579–587PubMedCrossRef Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL, Italian Association of the Study of the Liver Disease (AISF) (2007) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45:579–587PubMedCrossRef
24.
Zurück zum Zitat Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M (1999) Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124–1130PubMedCrossRef Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M (1999) Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124–1130PubMedCrossRef
25.
Zurück zum Zitat Ushitora Y, Tashiro H, Takahashi S, Amano H, Oshita A, Kobayashi T, Chayama K, Ohdan H (2011) Splenectomy in chronic hepatic disorders: portal vein thrombosis and improvement of liver function. Dig Surg 28:9–14PubMedCrossRef Ushitora Y, Tashiro H, Takahashi S, Amano H, Oshita A, Kobayashi T, Chayama K, Ohdan H (2011) Splenectomy in chronic hepatic disorders: portal vein thrombosis and improvement of liver function. Dig Surg 28:9–14PubMedCrossRef
26.
Zurück zum Zitat Yamamoto N, Okano K, Oshima M, Akamoto S, Fujiwara M, Tani J, Miyoshi H, Yoneyama H, Masaki T, Suzuki Y (2015) Laparoscopic splenectomy for patients with liver cirrhosis: improvement of liver function in patients with Child-Pugh class B. Surgery 158:1538–1544PubMedCrossRef Yamamoto N, Okano K, Oshima M, Akamoto S, Fujiwara M, Tani J, Miyoshi H, Yoneyama H, Masaki T, Suzuki Y (2015) Laparoscopic splenectomy for patients with liver cirrhosis: improvement of liver function in patients with Child-Pugh class B. Surgery 158:1538–1544PubMedCrossRef
27.
Zurück zum Zitat Imura S, Shimada M, Utsunomiya T, Morine Y, Ikemoto T, Mori H, Miyoshi H, Yoneyama H, Masaki T, Suzuki Y (2010) Impact of splenectomy in patients with liver cirrhosis: results from 18 patients in a single center experience. Hepatol Res 40:894–900PubMedCrossRef Imura S, Shimada M, Utsunomiya T, Morine Y, Ikemoto T, Mori H, Miyoshi H, Yoneyama H, Masaki T, Suzuki Y (2010) Impact of splenectomy in patients with liver cirrhosis: results from 18 patients in a single center experience. Hepatol Res 40:894–900PubMedCrossRef
28.
Zurück zum Zitat Nakamura T, Sakata R, Ueno T, Sata M, Ueno H (2000) Inhibition of transforming growth factor-ß prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 32:247–255PubMedCrossRef Nakamura T, Sakata R, Ueno T, Sata M, Ueno H (2000) Inhibition of transforming growth factor-ß prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 32:247–255PubMedCrossRef
29.
Zurück zum Zitat Morinaga A, Ogata T, Kage M, Kinoshita H, Aoyagi S (2010) Comparison of liver regeneration after a splenectomy and splenic artery ligation in a dimethylnitrosamine-induced cirrhotic rat model. HPB (Oxford) 12:22–30CrossRef Morinaga A, Ogata T, Kage M, Kinoshita H, Aoyagi S (2010) Comparison of liver regeneration after a splenectomy and splenic artery ligation in a dimethylnitrosamine-induced cirrhotic rat model. HPB (Oxford) 12:22–30CrossRef
30.
Zurück zum Zitat Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA (1999) The role of TGF beta1 in initiating hepatic stellate cell activation in vivo. J Hepatol 30:77–87PubMedCrossRef Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA (1999) The role of TGF beta1 in initiating hepatic stellate cell activation in vivo. J Hepatol 30:77–87PubMedCrossRef
31.
Zurück zum Zitat Border WA, Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286–1292PubMedCrossRef Border WA, Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286–1292PubMedCrossRef
32.
Zurück zum Zitat Friedman SL (2007) A deer in the headlights: BAMBI meets liver fibrosis. Nat Med 13:1281–1282PubMedCrossRef Friedman SL (2007) A deer in the headlights: BAMBI meets liver fibrosis. Nat Med 13:1281–1282PubMedCrossRef
33.
Zurück zum Zitat Ueda S, Yamanoi A, Hishikawa Y, Dhar DK, Tachibana M, Nagasue N (2003) Transforming growth factor-beta1 released from the spleen exerts a growth inhibitory effect on liver regeneration in rats. Lab Investig 83:1595–1603PubMedCrossRef Ueda S, Yamanoi A, Hishikawa Y, Dhar DK, Tachibana M, Nagasue N (2003) Transforming growth factor-beta1 released from the spleen exerts a growth inhibitory effect on liver regeneration in rats. Lab Investig 83:1595–1603PubMedCrossRef
34.
Zurück zum Zitat Asanoma M, Ikemoto T, Mori H, Utsunomiya T, Imura S, Morine Y, Iwahashi S, Saito Y, Yamada S, Shimada M (2014) Cytokine expression in spleen affects progression of liver cirrhosis through liver-spleen cross-talk. Hepatol Res 44:1217–1223PubMedCrossRef Asanoma M, Ikemoto T, Mori H, Utsunomiya T, Imura S, Morine Y, Iwahashi S, Saito Y, Yamada S, Shimada M (2014) Cytokine expression in spleen affects progression of liver cirrhosis through liver-spleen cross-talk. Hepatol Res 44:1217–1223PubMedCrossRef
35.
Zurück zum Zitat Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274:1379–1383PubMedCrossRef Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274:1379–1383PubMedCrossRef
36.
Zurück zum Zitat Castelino DJ, Salem HH (1997) Natural anticoagulants and the liver. J Gastroenterol Hepatol 12:77–1283PubMedCrossRef Castelino DJ, Salem HH (1997) Natural anticoagulants and the liver. J Gastroenterol Hepatol 12:77–1283PubMedCrossRef
37.
Zurück zum Zitat Hoefer J, Ulmer H, Kilo J, Margreiter R, Grimm M, Mair P, Ruttmann E, Innsbruck Liver-in-Heart-Failure Program (2017) Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support. J Thorac Cardiovasc Surg 153:1374–1382PubMedCrossRef Hoefer J, Ulmer H, Kilo J, Margreiter R, Grimm M, Mair P, Ruttmann E, Innsbruck Liver-in-Heart-Failure Program (2017) Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support. J Thorac Cardiovasc Surg 153:1374–1382PubMedCrossRef
38.
Zurück zum Zitat Mizuguchi T, Kawamoto M, Meguro M, Son S, Nakamura Y, Harada K, Shibata T, Ota S, Hirata K (2012) Serum antithrombin III level is well correlated with multiple indicators for assessment of liver function and diagnostic accuracy for predicting postoperative liver failure in hepatocellular carcinoma patients. Hepatogastroenterology 59:551–557PubMed Mizuguchi T, Kawamoto M, Meguro M, Son S, Nakamura Y, Harada K, Shibata T, Ota S, Hirata K (2012) Serum antithrombin III level is well correlated with multiple indicators for assessment of liver function and diagnostic accuracy for predicting postoperative liver failure in hepatocellular carcinoma patients. Hepatogastroenterology 59:551–557PubMed
39.
Zurück zum Zitat Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ (1982) Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 60:261–264PubMedCrossRef Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ (1982) Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 60:261–264PubMedCrossRef
41.
Zurück zum Zitat Choi YJ, Baik SK, Park DH, Kim MY, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW (2003) Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis. Gastroenterol Hepatol 18:424–429CrossRef Choi YJ, Baik SK, Park DH, Kim MY, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW (2003) Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis. Gastroenterol Hepatol 18:424–429CrossRef
42.
Zurück zum Zitat Kim G, Cho YZ, Baik SK, Kim MY, Hong WK, Kwon SO (2015) The accuracy of ultrasonography for the evaluation of portal hypertension in patients with cirrhosis: a systematic review. Korean J Radiol 16:314–324PubMedPubMedCentralCrossRef Kim G, Cho YZ, Baik SK, Kim MY, Hong WK, Kwon SO (2015) The accuracy of ultrasonography for the evaluation of portal hypertension in patients with cirrhosis: a systematic review. Korean J Radiol 16:314–324PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Tasu JP, Rocher L, PEletier G, Kuoch V, Kulh E, Miquel A, Buffet C, BlEry M (2002) Hepatic venous pressure gradients measured by duplex ultrasound. Clin Radiol 57:746–752PubMedCrossRef Tasu JP, Rocher L, PEletier G, Kuoch V, Kulh E, Miquel A, Buffet C, BlEry M (2002) Hepatic venous pressure gradients measured by duplex ultrasound. Clin Radiol 57:746–752PubMedCrossRef
44.
Zurück zum Zitat Schneider AW, Kalk JF, Klein CP (1999) Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. J Hepatol 30:876–881PubMedCrossRef Schneider AW, Kalk JF, Klein CP (1999) Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. J Hepatol 30:876–881PubMedCrossRef
45.
Zurück zum Zitat Taourel P, Blanc P, Dauzat M, Chabre M, Pradel J, Gallix B, Larrey D, Bruel JM (1998) Doppler study of mesenteric, hepatic, and portal circulation in alcoholic cirrhosis: relationship between quantitative Doppler measurements and the severity of portal hypertension and hepatic failure. Hepatology 28:932–936PubMedCrossRef Taourel P, Blanc P, Dauzat M, Chabre M, Pradel J, Gallix B, Larrey D, Bruel JM (1998) Doppler study of mesenteric, hepatic, and portal circulation in alcoholic cirrhosis: relationship between quantitative Doppler measurements and the severity of portal hypertension and hepatic failure. Hepatology 28:932–936PubMedCrossRef
46.
Zurück zum Zitat Kim MY, Choi H, Baik SK, Yea CJ, Won CS, Byun JW, Park SY, Kwon YH, Kim JW, Kim HS, Kwon SO, Kim YJ, Cha SH, Chang SJ (2010) Portal hypertensive gastropathy: correlation with portal hypertension and prognosis in cirrhosis. Dig Dis Sci 55:3561–3567PubMedCrossRef Kim MY, Choi H, Baik SK, Yea CJ, Won CS, Byun JW, Park SY, Kwon YH, Kim JW, Kim HS, Kwon SO, Kim YJ, Cha SH, Chang SJ (2010) Portal hypertensive gastropathy: correlation with portal hypertension and prognosis in cirrhosis. Dig Dis Sci 55:3561–3567PubMedCrossRef
Metadaten
Titel
Effects of laparoscopic splenectomy and azygoportal disconnection on liver synthesis function and cirrhosis: a 2-year prospective study
verfasst von
Dou-Sheng Bai
Bao-Huan Zhou
Jian-Jun Qian
Chi Zhang
Sheng-Jie Jin
Guo-Qing Jiang
Publikationsdatum
09.12.2019
Verlag
Springer US
Erschienen in
Surgical Endoscopy / Ausgabe 11/2020
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-019-07307-7

Weitere Artikel der Ausgabe 11/2020

Surgical Endoscopy 11/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.